Mutagenic Effects of Ribavirin on Hepatitis E Virus—Viral Extinction versus Selection of Fitness-Enhancing Mutations
Hepatitis E virus (HEV), an important agent of viral hepatitis worldwide, can cause severe courses of infection in pregnant women and immunosuppressed patients. To date, HEV infections can only be treated with ribavirin (RBV). Major drawbacks of this therapy are that RBV is not approved for administ...
Main Authors: | Daniel Todt, Stephanie Walter, Richard J. P. Brown, Eike Steinmann |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2016-10-01
|
Series: | Viruses |
Subjects: | |
Online Access: | http://www.mdpi.com/1999-4915/8/10/283 |
Similar Items
-
Extended treatment with interferon and ribavirin in a hemodialysis patient with chronic hepatitis C
by: Aline Gonzalez Vigani, et al. -
Efficacy and safety of sofosbuvir plus ribavirin for Korean patients with hepatitis C virus genotype 2 infection: A retrospective multi-institutional study
by: Young Min Kim, et al.
Published: (2018-09-01) -
Hepatitis E Virus Drug Development
by: Volker Kinast, et al.
Published: (2019-05-01) -
Plasma Hepatitis E Virus Kinetics in Solid Organ Transplant Patients Receiving Ribavirin
by: Sebastien Lhomme, et al.
Published: (2019-07-01) -
Efficacy and safety of ombitasvir/paritaprevir/ritonavir ± dasabuvir ± ribavirin in treatment of patients with chronic hepatitis C in the Republic of Srpska: A real-life study
by: Verhaz Antonija, et al.
Published: (2019-01-01)